Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price
on Aug 26, 2024
Agile Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 2.85 | 2.56 | 5.25 | 19.14 | 14.46 | 34.48 | Upgrade
|
| Short-Term Investments | - | - | - | - | 40.01 | - | Upgrade
|
| Cash & Short-Term Investments | 2.85 | 2.56 | 5.25 | 19.14 | 54.47 | 34.48 | Upgrade
|
| Cash Growth | 2.26% | -51.26% | -72.60% | -64.86% | 57.98% | 339.17% | Upgrade
|
| Receivables | 4.55 | 3.39 | 3.38 | 1.53 | 0.87 | - | Upgrade
|
| Inventory | 5.79 | 2.74 | 1.33 | 0.97 | - | - | Upgrade
|
| Prepaid Expenses | 0.13 | 0.44 | 0.63 | 0.78 | 0.68 | 0.84 | Upgrade
|
| Other Current Assets | 1.12 | 0.4 | 0.78 | 1.51 | 0.77 | - | Upgrade
|
| Total Current Assets | 14.44 | 9.53 | 11.36 | 23.93 | 56.79 | 35.32 | Upgrade
|
| Property, Plant & Equipment | 0.28 | 0.49 | 0.87 | 13.4 | 14.38 | 14.2 | Upgrade
|
| Other Long-Term Assets | 0.24 | 0.24 | 2.01 | 2.01 | 1.9 | 0.02 | Upgrade
|
| Total Assets | 14.96 | 10.26 | 14.24 | 39.33 | 73.06 | 49.54 | Upgrade
|
| Accounts Payable | 16.54 | 9.57 | 7.73 | 8.71 | 3.87 | 1.82 | Upgrade
|
| Accrued Expenses | 9.4 | 9.13 | 3.91 | 3.56 | 3.35 | 1.8 | Upgrade
|
| Short-Term Debt | - | 0.19 | - | - | - | - | Upgrade
|
| Current Portion of Long-Term Debt | - | 1.52 | 1.43 | 16.83 | - | - | Upgrade
|
| Current Portion of Leases | 0.29 | 0.37 | 0.32 | 0.18 | 0.14 | 0.17 | Upgrade
|
| Total Current Liabilities | 26.23 | 20.78 | 13.39 | 29.28 | 7.35 | 3.8 | Upgrade
|
| Long-Term Debt | - | - | - | - | 16.38 | - | Upgrade
|
| Long-Term Leases | - | 0.1 | 0.47 | 0.78 | - | - | Upgrade
|
| Other Long-Term Liabilities | 10.65 | 5.7 | 5.93 | 5.36 | - | - | Upgrade
|
| Total Liabilities | 36.88 | 26.57 | 19.79 | 35.42 | 23.73 | 3.8 | Upgrade
|
| Common Stock | 0.01 | 0 | - | - | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 411.84 | 406.85 | 403.16 | 387.21 | 361.54 | 306.11 | Upgrade
|
| Retained Earnings | -433.76 | -423.17 | -408.7 | -383.29 | -312.22 | -260.37 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 0 | - | Upgrade
|
| Total Common Equity | -21.91 | -16.32 | -5.55 | 3.92 | 49.33 | 45.75 | Upgrade
|
| Shareholders' Equity | -21.91 | -16.32 | -5.55 | 3.92 | 49.33 | 45.75 | Upgrade
|
| Total Liabilities & Equity | 14.96 | 10.26 | 14.24 | 39.33 | 73.06 | 49.54 | Upgrade
|
| Total Debt | 0.29 | 2.17 | 2.21 | 17.79 | 16.52 | 0.17 | Upgrade
|
| Net Cash (Debt) | 2.56 | 0.39 | 3.04 | 1.35 | 37.95 | 34.31 | Upgrade
|
| Net Cash Growth | 2712.09% | -87.31% | 124.65% | -96.44% | 10.62% | 336.98% | Upgrade
|
| Net Cash Per Share | 0.59 | 0.18 | 7.02 | 27.84 | 896.32 | 1388.05 | Upgrade
|
| Filing Date Shares Outstanding | 6.9 | 6.86 | 0.93 | 0.07 | 0.04 | 0.03 | Upgrade
|
| Total Common Shares Outstanding | 6.9 | 2.96 | 0.86 | 0.06 | 0.04 | 0.03 | Upgrade
|
| Working Capital | -11.79 | -11.25 | -2.03 | -5.35 | 49.43 | 31.52 | Upgrade
|
| Book Value Per Share | -3.17 | -5.51 | -6.45 | 64.50 | 1126.67 | 1310.56 | Upgrade
|
| Tangible Book Value | -21.91 | -16.32 | -5.55 | 3.92 | 49.33 | 45.75 | Upgrade
|
| Tangible Book Value Per Share | -3.17 | -5.51 | -6.45 | 64.50 | 1126.67 | 1310.56 | Upgrade
|
| Machinery | - | 0.25 | 0.25 | 14.6 | 14.33 | 14.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.